Site Editor

Gregory J. Riely, MD, PhD

Advertisement
Advertisement

Heather Wakelee, MD, on Clinical Implications of Latest Findings From IMpower010: Atezolizumab vs Best Supportive Care for NSCLC

Posted: Tuesday, June 11, 2024

Heather Wakelee, MD, of Stanford University Medical Center, discusses practical clinical questions regarding the latest phase III findings showing that atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC).


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.